Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to -$628.8 million.

  • Outlook Therapeutics' Retained Earnings fell 1955.87% to -$628.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$628.8 million, marking a year-over-year decrease of 1955.87%. This contributed to the annual value of -$605.7 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Outlook Therapeutics reported Retained Earnings of -$628.8 million as of Q4 2025, which was down 1955.87% from -$605.7 million recorded in Q3 2025.
  • In the past 5 years, Outlook Therapeutics' Retained Earnings registered a high of -$525.9 million during Q4 2024, and its lowest value of -$628.8 million during Q4 2025.